Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Terminated 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Leiomyoma 4Menorrhagia 2

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × vilaprisan × Clear all
NCT03194646 2025-07-28

ASTEROID 6

Bayer

Phase 3 Terminated
1,272 enrolled 16 charts

Leiomyoma

NCT03400943 2023-05-03

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

Bayer

Phase 3 Terminated
93 enrolled 19 charts

Leiomyoma, Menorrhagia

NCT03400956 2022-06-30

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

Bayer

Phase 3 Terminated
103 enrolled 18 charts

Leiomyoma, Menorrhagia

NCT02131662 2017-12-08

ASTEROID 1

Bayer

Phase 2 Completed
309 enrolled 24 charts

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡